X4 PHARMACEUTICALS, INC Amortization of Intangible Assets
X4 PHARMACEUTICALS, INC (XFOR) reported Amortization of Intangible Assets of $600.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2025-11-05
- X4 PHARMACEUTICALS, INC amortization of intangible assets for the quarter ending 2025-09-30 was $200.00K, a 0.00% change year-over-year.
- X4 PHARMACEUTICALS, INC amortization of intangible assets for the quarter ending 2024-12-31 was $200.00K.
- X4 PHARMACEUTICALS, INC amortization of intangible assets for the quarter ending 2024-09-30 was $200.00K.
- X4 PHARMACEUTICALS, INC amortization of intangible assets for the quarter ending 2024-06-30 was $100.00K.
- X4 PHARMACEUTICALS, INC amortization of intangible assets for fiscal 2024 was $500.00K.
- X4 PHARMACEUTICALS, INC amortization of intangible assets for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC amortization of intangible assets for fiscal 2022 was $0.00.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $600.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $400.00K 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $400.00K derived: sum of 2 quarters · filed 2025-03-26 | $500.00K derived: sum of 3 quarters · filed 2025-03-26 | $500.00K 10-K · filed 2025-03-26 |
| 2024-09-30 | $200.00K 10-Q · filed 2024-11-13 | $300.00K derived: sum of 2 quarters · filed 2024-11-13 | $300.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-08 | $100.00K 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |